The Impact of Enzalutamide on the Prostate Cancer Patient Experience: A Summary Review of Health-Related Quality of Life across Pivotal Clinical Trials.
anti-neoplastic agents
cancer pain
prostatic neoplasms
quality of life
treatment outcome
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
23 Nov 2021
23 Nov 2021
Historique:
received:
04
10
2021
revised:
12
11
2021
accepted:
18
11
2021
entrez:
10
12
2021
pubmed:
11
12
2021
medline:
11
12
2021
Statut:
epublish
Résumé
This review examines the impact of treatment with enzalutamide on health-related quality of life (HRQoL) in prostate cancer patients across the disease continuum based on pivotal clinical trials. We assessed the effect of enzalutamide on pain, symptom burden and overall HRQoL from randomized controlled trials. Patient experience was evaluated in men with metastatic hormone-sensitive prostate cancer (mHSPC), non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-resistant prostate cancer (mCRPC) (pre-chemotherapy and post-chemotherapy). Patients across the disease continuum reported a generally positive status at baseline, with relatively low levels of pain and impairment due to cancer-related symptoms and high HRQoL. For patients with earlier-state prostate cancer, pain and symptom-related burden were low at study entry and remained so, regardless of whether patients received enzalutamide or control treatment. Patients with more advanced disease reported mitigation in pain and symptom burden while receiving treatment with enzalutamide. Enzalutamide was observed to slow deterioration of overall HRQoL most for patients with nmCRPC or mCRPC (statistical significance for between-group difference in median time to deterioration: mHSPC (confirmed)
Identifiants
pubmed: 34884981
pii: cancers13235872
doi: 10.3390/cancers13235872
pmc: PMC8657254
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Astellas Pharma Inc.
ID : NA
Organisme : Pfizer Inc.
ID : NA
Références
Adv Ther. 2020 Jan;37(1):512-526
pubmed: 31813087
N Engl J Med. 2019 Jul 11;381(2):121-131
pubmed: 31157964
Value Health. 2009 Jan-Feb;12(1):124-9
pubmed: 18647260
Lancet Oncol. 2015 May;16(5):509-21
pubmed: 25888263
N Engl J Med. 2014 Jul 31;371(5):424-33
pubmed: 24881730
Ann Acad Med Singap. 1994 Mar;23(2):129-38
pubmed: 8080219
Lancet Oncol. 2019 Apr;20(4):556-569
pubmed: 30770294
Lancet Oncol. 2019 Nov;20(11):1518-1530
pubmed: 31578173
Clin Adv Hematol Oncol. 2013 Jan;11(1):14-23
pubmed: 23416859
N Engl J Med. 2018 Jun 28;378(26):2465-2474
pubmed: 29949494
Ann Oncol. 2015 Jan;26(1):179-185
pubmed: 25361992
Eur Urol. 2020 Oct;78(4):603-614
pubmed: 32336645
Lancet Oncol. 2013 Nov;14(12):1193-9
pubmed: 24075621
Urology. 1997 Dec;50(6):920-8
pubmed: 9426724
Eur J Cancer. 2013 Nov;49(17):3648-57
pubmed: 23973186
Lancet Oncol. 2019 Mar;20(3):436-447
pubmed: 30713036
Lancet Oncol. 2014 Sep;15(10):1147-56
pubmed: 25104109
Patient. 2017 Oct;10(5):567-578
pubmed: 28285412
J Clin Oncol. 2019 Nov 10;37(32):2974-2986
pubmed: 31329516
Eur J Cancer. 2018 Nov;103:78-87
pubmed: 30218976
Lancet Oncol. 2018 Feb;19(2):194-206
pubmed: 29326030
Lancet Oncol. 2019 Mar;20(3):325-326
pubmed: 30713037
Patient. 2019 Feb;12(1):57-67
pubmed: 30519830
Eur Urol Focus. 2017 Oct;3(4-5):480-486
pubmed: 28753787
N Engl J Med. 2012 Sep 27;367(13):1187-97
pubmed: 22894553
Health Policy. 1990 Dec;16(3):199-208
pubmed: 10109801
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Eval Health Prof. 2005 Jun;28(2):172-91
pubmed: 15851772
Health Qual Life Outcomes. 2007 Dec 21;5:70
pubmed: 18154669